Abstract: The present application discloses compounds of Formula (I): (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, and R4 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds of Formula I or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: The present application discloses compounds having the following formula: or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined in the specification, as well as methods of making and using the compounds disclosed herein for treating or ameliorating an IL-17 mediated syndrome, disorder and/or disease.

Abstract: Systems and methods are provided for a magnetic coupling shade system for boats. The magnetic coupling shade system features a sheet of material that includes magnetic portions coupled with magnets disposed in locations of a boat. The locations of the boat include any of the hull, deck, superstructure, hardtop, or any other suitable surface of the boat. Magnets located on the hull are located within the interior of the hull. The sheet extends from the top to either or both of the port and starboard sides. The sheet can include a variety of materials, and a window portion for viewing through the sheet. In some embodiments, the window portion includes an entirety of the sheet with the magnetic portions attached to opposite edges of the window portion. The sheet is configured to be detached from the magnets and either suspended overhead or rolled upward when not in use.

Abstract: Systems and methods are provided for a magnetic coupling shade system for boats. The magnetic coupling shade system comprises a sheet of material that includes magnetic portions coupled with magnets disposed in locations of a boat. The locations of the boat include any of the hull, deck, superstructure, hardtop, or any other suitable surface of the boat. Magnets located on the hull are located within the interior of the hull. The sheet extends from the top to either or both of the port and starboard sides. The sheet can comprise a variety of materials, and may include a window portion for viewing through the sheet. In some embodiments, the window portion comprises an entirety of the sheet with the magnetic portions attached to opposite edges of the window portion. The sheet is configured to be detached from the magnets and either suspended overhead or rolled upward when not in use.